Business
Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer
SAN DIEGO, April 5, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, April 5, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Michael MacLean, currently the chief financial officer, has expanded his role to include responsibilities as chief business officer.\n\n \n \n \n \n \n \n\n \n\"Mike's leadership, strategic thinking and operating expertise have been instrumental in the success of Avidity over these past two years as we transitioned into a publicly-traded, clinical-stage biopharmaceutical company,\" said Sarah Boyce, president and chief executive officer. \"I am pleased that he is taking on these expanded responsibilities as his input and guidance will be invaluable to the team as we advance our clinical development programs and progress our innovative AOC platform technology across a range of therapeutic areas.\"\nAs the chief financial and chief business officer, Mr. MacLean now leads finance, business development, supply chain and investor relations as Avidity advances its AOC platform and works toward the goal of having three distinct rare disease programs in the clinic by the end of 2022.\nMr. MacLean brings decades of industry experience to Avidity, with deep experience in funding biotechnology companies, developing strategic plans, partnering novel technologies and advancing novel therapies in the rare and orphan disease areas through to commercialization. Prior to joining Avidity, Mr. MacLean served as chief financial officer of Akcea Therapeutics, Inc. where he led the buildout of Akcea's financial and global infrastructure. Prior to Akcea, Mr. MacLean served as chief financial officer of PureTech Health, plc, as well as chief accounting officer of Biogen Inc. where he led the company's worldwide finance operations. \n\"I am proud to be part of the Avidity team that is well on the path to realizing its vision to profoundly improve the lives of people affected by serious diseases. We have assembled a talented team and I look forward to continuing to work closely with them and other senior leaders as we deliver on our vision,\" said Mr. MacLean, chief financial and chief business officer.\nAbout AvidityAvidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of...